Journal of Clinical Immunology & Microbiology
Cure8 research brief
Why This Matters
The study tests combined neutralization of two pro-inflammatory cytokines plus IL‑10 in a mouse colitis model and reports reduced inflammation and restored macrophage cellular pathways, which may inform future IBD therapy research.
Who Should Pay Attention
Researchers, translational scientists, and clinicians interested in cytokine-targeted therapies and immune mechanisms in IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is an abstract of an animal (mouse) study testing a combination approach: antibodies that neutralize TNF‑α and IL‑1β, with supplemental IL‑10, in a DSS model of colitis. Treated mice showed reduced markers of inflammation, oxidative stress, and altered apoptosis/autophagy protein expression in splenic macrophages compared with DSS‑only mice.
The report describes changes in macrophage signaling and protein markers (NF‑κB, ROS, Beclin‑1, LC3‑II) consistent with reduced inflammation and restored cellular homeostasis in the treated group. This is preclinical research in mice and does not provide evidence about safety or effectiveness in people with IBD.
It suggests a multi‑targeted immune approach worth further study, but it is not a clinical recommendation.
Keep In Mind
Preclinical (mouse) model; results are mechanistic and exploratory and do not establish safety or efficacy in people.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of Clinical Immunology & Microbiology
PublisherAthenaeum Scientific Publishers
AuthorsBiswadev Bishayi, Gopinath Mukherjee, Shakhi Ghosh +1 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 5, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Heat-Inactivated Lacticaseibacillus paracasei PC-01 Alleviates DSS-Induced Colitis in Mice by Modulating Gut Microbiota and Intestinal Barrier Function
This preclinical study suggests a heat‑inactivated probiotic strain reduced colitis signs in mice and changed gut microbes and inflammatory pathways—findings that could inform future research into microbiome‑based or...
Five-flavor Sophora flavescens Enteric-coated Capsules Alleviate Experimental Colitis and Ferroptosis-related Changes.
This preclinical study suggests an herbal capsule formulation reduced colitis severity and shifted markers of oxidative stress, inflammation, and ferroptosis in mice — signaling possible biological pathways for future...
Effects of Anacyclus pyrethrum L on a mouse model of inflammatory bowel disease and its influence on intestinal barrier function and gut microbiota.
This preclinical study reports that an extract of Anacyclus pyrethrum reduced colitis signs in a mouse DSS model and was linked to improved intestinal barrier markers, lower innate immune receptor expression, changes in...